


RECEIVED  
#18  
5-7-01



# CONTINUED PROSECUTION APPLICATION (CPA) 2001 REQUEST TRANSMITTAL

Submit an original, and a duplicate for fee processing.  
(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

TECH CENTER 1600-0000

**DUPLICATE**

Address to:

Commissioner for Patents  
Box CPA  
Washington, DC 20231

Attorney Docket No.	766.21
First Named Inventor	Tetsuyoshi Ishiwata
Examiner Name	Peter Brunovskis
Group Art Unit	1632
Express Mail Label No.	

This is a request for a  continuation or  divisional application under 37 CFR 1.53(d),  
(continued prosecution application (CPA)) of prior application number 09/090,672, filed on June 4, 1998, entitled IgA NEPHROPATHY-RELATED GENES

## NOTES

**FILING QUALIFICATIONS:** The prior application identified above must be a nonprovisional application that is either: (1) complete as defined by 37 CFR § 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 U.S.C. § 154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

**C-I-P NOT PERMITTED:** A continuation-in-part application cannot be filed as a CPA under 37 CFR § 1.53(d), but must be filed under 37 CFR § 1.53(b).

**EXPRESS ABANDONMENT OF PRIOR APPLICATION:** The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR § 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

**ACCESS TO PRIOR APPLICATION:** The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR § 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

**35 U.S.C. 120 STATEMENT:** In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR § 1.78(a).

1.  Enter the unentered amendment previously filed on April 6, 2001 under 37 CFR § 1.116 in the prior nonprovisional application.
2. a.  A preliminary amendment is enclosed.  
b.  The applicant(s) presently intend(s) to file additional papers in this case shortly. Should the Examiner take this case up for action before receiving such papers, it is respectfully requested that the Examiner contact the attorneys for the applicant(s).
3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR § 1.53(d)(4).  
a.  DELETE the following inventor(s) named in the prior nonprovisional application:  
  
  
  
b.  The inventors to be deleted are set forth on a separate sheet attached hereto.
4.  An Associate Power of Attorney is enclosed.
5. Information Disclosure Statement (IDS) is enclosed:  
a.  PTO-1449  
b.  Copies of IDS Citations

05/04/2001 GTEFFERA 00000097 09090672

01 FC:131

710.00 00

CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR § 1.16(c) or (i))	8 - 20 =	0	X \$ 18.00 =	\$0.00
	INDEPENDENT CLAIMS (37 CFR § 1.16(b) or (i))	2 - 3 =	0	X \$ 80.00 =	\$0.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR § 1.16(d))			\$270.00 =	\$0.00
				BASIC FEE (37 CFR § 1.16(a))	\$ 710.00
				Total of above Calculations =	\$710.00
	Reduction by 50% for filing by small entity (Note 37 CFR §§ 1.9, 1.27, 1.28).				
				TOTAL =	\$710.00

6. Small entity status

- a.  A Small entity statement is enclosed
- b.  A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- c.  Is no longer claimed.

7.  Small entity status: Applicant claims small entity status. See 37 CFR § 1.27.

8.  A check in the amount of \$ 710.00 is enclosed.

9. The Commissioner is hereby authorized to credit overpayments or charge deficiencies in the following fees to Deposit Account No. 06-1205:

- a.  Fees required under 37 CFR § 1.16.
- b.  Fees required under 37 CFR § 1.17.
- c.  Fees required under 37 CFR § 1.18.

10.  Applicant requests suspension of action under 37 CFR § 1.103(b) for three months. (Fee of \$130.00 required under 37 CFR § 1.17(i) is enclosed).

11. a.  Receipt For Facsimile Transmitted CPA (PTO/SB/29A).

b.  Return Receipt Postcard (Should be specifically itemized. See MPEP 503).


12.  Other Petition for Extension of Time and \$280.00 check

NOTE: *The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below*

13. NEW CORRESPONDENCE ADDRESS

<input type="checkbox"/>	Customer Number or Bar Code Label	<input type="checkbox"/> (Insert Customer No. or Attach bar code label here)		<input type="checkbox"/> or <input type="checkbox"/> New correspondence address below
NAME				
ADDRESS				
CITY	STATE	ZIP CODE		
COUNTRY	TELEPHONE	FAX		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	Lawrence S. Perry
SIGNATURE	
REGISTRATION NO.	31,865
DATE	May 2, 2001

RECEIVED

MAY 04 2001

#19C  
K  
5-7-01



766.21

PATENT APPLICATION  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
TETSUYOSHI ISHIWATA et al. ) : Examiner: Peter Brunovskis  
Application No.: 09/090,672 ) : Group Art Unit: 1632  
Filed: June 4, 1998 ) :  
For: IgA NEPHROPATHY-RELATED ) :  
GENES : May 2, 2001

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to action on the merits, please amend the  
above-identified application as follows:

IN THE CLAIMS:

Please amend Claim 2 to read as follows. A marked-up copy of Claim 2, showing the changes made thereto, is attached.

2. (Amended) An isolated DNA comprising a  
nucleotide sequence identical to any continuous 10 to 50  
residues in a nucleotide sequence selected from the